[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 44 of about 44
1. Smith Y, Hadway P, Ahmed S, Perry MJ, Corbishley CM, Watkin NA: Penile-preserving surgery for male distal urethral carcinoma. BJU Int; 2007 Jul;100(1):82-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile-preserving surgery for male distal urethral carcinoma.
  • OBJECTIVE: To evaluate medium-term outcome data from patients with distal urethral cancers treated with penile-preserving surgery.
  • PATIENTS AND METHODS: We analysed prospectively 18 consecutive men referred for the management of urethral carcinoma.
  • Tumours were staged according to the Tumour-Node-Metastasis classification and the patients offered penile-preserving surgery when tumours were limited to the glanular or penile urethra.
  • RESULTS: All 18 patients were suitable for penile-preserving surgery; the procedures were: three hypospadias formation with or without topical chemotherapy; four buccal mucosa urethroplasty; three glansectomy and reconstruction; six glansectomy, distal corporectomy, reconstruction and hypospadias formation; two urethrectomy with or with no excision of adjacent tunica albuginea.
  • CONCLUSION: Medium-term data show that penile-preserving surgery is a feasible treatment for men with distal urethral carcinoma, providing excellent local control without prejudicing survival; a longer follow-up is needed.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Penis / surgery. Urethral Neoplasms / surgery. Urologic Surgical Procedures, Male / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Feasibility Studies. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488307.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA, European Association of Urology: [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma]. Actas Urol Esp; 2010 Jan;34(1):51-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
  • [Transliterated title] Actualización de las Guías Clínicas de la Asociación Europea de Urología sobre el carcinoma vesical músculo-invasivo y metastásico.
  • CONTEXT: New data regarding diagnosis and treatment of muscle-invasive and metastatic bladder cancer (MiM-BC) has emerged and led to an update of the European Association of Urology (EAU) guidelines for MiM-BC.
  • EVIDENCE ACQUISITION: A comprehensive workup of the literature obtained from Medline, the Cochrane central register of systematic reviews, and reference lists in publications and review articles was developed and screened by a group of urologists, oncologists, and radiologist appointed by the EAU Guideline Committee.
  • EVIDENCE SYNTHESIS: The diagnosis of muscle-invasive bladder cancer (BCa) is made by transurethral resection (TUR) and following histopathologic evaluation.
  • Patients with confirmed muscle-invasive BCa should be staged by computed tomography (CT) scans of the chest, abdomen, and pelvis, if available.
  • Adjuvant chemotherapy is currently only advised within clinical trials.
  • Radical cystectomy (RC) is the treatment of choice for both sexes, and lymph node dissection should be an integral part of cystectomy.
  • An orthotopic bladder substitute should be offered to both male and female patients lacking any contraindications, such as no tumour at the level of urethral dissection.
  • Multimodality bladder-preserving treatment in localised disease is currently regarded only as an alternative in selected, well-informed, and compliant patients for whom cystectomy is not considered for clinical or personal reasons.
  • c) functional deterioration at particular sites; and d) consideration of treatment of a recurrence.
  • In metastatic disease, the first-line treatment for patients fit enough to sustain cisplatin is cisplatin-containing combination chemotherapy.
  • Presently, there is no standard second-line chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms. Urology / standards
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cystectomy / methods. Diagnostic Imaging. Evidence-Based Medicine. Female. Humans. Lymph Node Excision. Male. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging / methods. Palliative Care. Risk Factors. Urinary Diversion / methods

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223133.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Dalbagni G, Donat SM, Eschwège P, Herr HW, Zelefsky MJ: Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol; 2001 Nov;166(5):1759-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra.
  • PURPOSE: We evaluated a multimodality approach to locally advanced urethral carcinoma in women.
  • MATERIALS AND METHODS: Between August 1996 and July 1999, 6 women were treated for locally advanced carcinoma of the urethra with anterior pelvic exenteration followed by high dose 192iridium intraoperative radiation therapy.
  • Four of the 6 patients were also treated with neoadjuvant or concomitant platinum based chemotherapy.
  • [MeSH-major] Brachytherapy. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Pelvic Exenteration. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11586218.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Eng TY, Naguib M, Galang T, Fuller CD: Retrospective study of the treatment of urethral cancer. Am J Clin Oncol; 2003 Dec;26(6):558-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of the treatment of urethral cancer.
  • Urethral cancer is rare, encompassing less than 1% of all malignancies.
  • Therefore, it is imperative to share all available information regarding urethral cancer treatment via reportage of pertinent cases, thus enabling more complete comprehension and decision-making options by both clinicians and researchers.
  • A retrospective review of 18 consecutive patients with primary urethral cancer was performed.
  • An analysis was performed of clinical stage, treatment modality, and outcome.
  • Seven of 10 patients with low-stage diagnosis remained disease free.
  • Comparatively, only one of eight patients with high-stage cancer had no apparent disease.
  • Patients with advanced cancer treated with surgery alone had a shorter disease-free survival (23.3 months) versus those treated with combination chemo/radiation therapy (45.2 months).
  • Patients with low-stage disease exhibited increased survival with single-modality therapy.
  • However, patients with advanced cancer benefited from combined treatment using chemotherapy and radiation therapy.
  • [MeSH-major] Urethral Neoplasms / therapy

  • Genetic Alliance. consumer health - Urethral cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14663371.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Frickmann H, Jungblut S, Hanke P, Bargon J: [Tuberculosis induced by Bacillus Calmette-Guerin immuno-prophylaxis -- case study]. Pneumologie; 2004 Nov;58(11):773-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of miliary tuberculosis induced by Bacillus Calmette-Guerin (BCG) as a complication of an infection after BCG-instillation therapy into the bladder because of bladder carcinoma.
  • Bacilli surely entered blood circulation via an urethral lesion because of a difficult catheterisation.
  • CT showed a miliary patten and the diagnosis was confirmed by bronchoscopy: transbronchial biopsy showed granulomatous infiltration and an acid-fast rod-bacterium was detected in bronchial slime.
  • Symptoms vanished after a consequent antituberculous triple therapy regime and the patient left hospital in a good general state of health.
  • [MeSH-minor] Antitubercular Agents / therapeutic use. Humans. Infection / etiology. Instillation, Drug. Male. Middle Aged. Treatment Outcome. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534773.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antitubercular Agents; 0 / BCG Vaccine
  •  go-up   go-down


6. Varol C, Thalmann GN, Burkhard FC, Studer UE: Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol; 2004 Sep;172(3):937-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution.
  • PURPOSE: With the introduction of orthotopic bladder substitution after radical cystectomy in patients with invasive bladder cancer urethral recurrences have become a therapeutic challenge.
  • MATERIALS AND METHODS: We retrospectively evaluated our patients with urethral recurrences treated with a urethra sparing approach after orthotopic bladder substitution.
  • Depending on the extension of recurrence and eventual concomitant metastases patients were treated with urethrectomy, no treatment, systemic chemotherapy or intraurethral bacillus Calmette-Guerin (BCG).
  • Three times the common dose of BCG (ImmuCyst, Aventis, Paris, France or OncoTICE, Organon, West Orange, New Jersey) in 150 ml NaCl 0.9% was used for intraurethral BCG perfusion therapy according to an institutional protocol using a modified Foley catheter.
  • RESULTS: Between 1985 and 2001, 15 of 371 patients (4%) who received an orthotopic bladder substitute had urethral recurrence.
  • Two patients were treated with systemic chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin) alone due to metastatic disease and 10 received intraurethral BCG therapy.
  • Five of 6 patients (83%) with carcinoma in situ remained free of recurrence following treatment with BCG, while in 4 with papillary or invasive disease treatment failed.
  • Three patients underwent urethrectomy, including 2 following failed BCG therapy for papillary disease.
  • CONCLUSIONS: Carcinoma in situ urethral recurrence following orthotopic bladder substitution can be treated successfully with intraurethral BCG perfusion therapy in approximately 80% of patients.
  • However, papillary and invasive transitional cell urethral recurrence should be treated with urethrectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Cystectomy. Urethral Neoplasms / secondary. Urethral Neoplasms / therapy. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. BCG Vaccine / administration & dosage. Humans. Male. Middle Aged. Urethra / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15311003.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  •  go-up   go-down


7. Nicholson S, Tsang D, Summerton D: Aggressive combined-modality therapy for squamous cell carcinoma of the female urethra. Nat Clin Pract Urol; 2008 Oct;5(10):574-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive combined-modality therapy for squamous cell carcinoma of the female urethra.
  • INVESTIGATIONS: Pelvic examination under anesthetic by both a urologist and gynecologist, biopsy of the urethral tumor and of the cervix, pathological analysis, MRI of the pelvis, CT of the chest, abdomen and pelvis.
  • DIAGNOSIS: Poorly differentiated squamous cell carcinoma of the urethra, T4N0M0.
  • MANAGEMENT: The patient received two cycles of neoadjuvant TIP (paclitaxel, ifosfamide, cisplatin) chemotherapy, resulting in complete remission, followed by consolidative chemoradiation therapy (radiation therapy given with synchronous weekly cisplatin).
  • She remained relapse-free 48 months after diagnosis, with normal voiding and sexual function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762780.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Tiguert R, Ravery V, Madjar S, Gousse AE: [Acute urinary retention secondary to clear cell adenocarcinoma of the urethra]. Prog Urol; 2001 Feb;11(1):70-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute urinary retention secondary to clear cell adenocarcinoma of the urethra].
  • [Transliterated title] Rétention urinaire aiguë secondaire à un adénocarcinome à cellules claires de l'urèthre.
  • The authors report a case of primary clear cell cancer of the urethra in a woman presenting with acute urinary retention.
  • The diagnosis was based on cystoscopy and confirmed by histological examination of urethral biopsies.
  • Treatment consisted of urethrocystectomy with creation of an "Indiana pouch".
  • She was treated with 3 courses of chemotherapy (mitomycin and 5-fluorouracil) combined with radiotherapy.
  • This case report emphasizes the rarity of this histological type and describes the management of urinary retention in a woman when an underlying specific disease is suspected.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Urethral Neoplasms / complications. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11296650.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL: Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum; 2001 Apr;44(4):506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome analysis of HIV-positive patients with anal squamous cell carcinoma.
  • PURPOSE: With improved antiretroviral therapy, HIV-positive patients are achieving a longer life expectancy.
  • METHODS: We conducted a review based on our tumor registry from 1980 through 1999.
  • We identified 73 patients with anal squamous cell carcinoma treated at the University of Texas Southwestern Medical Center affiliated hospitals; 23 were HIV positive (18 had AIDS).
  • Data collected included age, CD4 count, treatment, complications, and survival; these data were analyzed by Student's t-test.
  • Those with squamous cell cancer of the anus were offered radiation therapy and chemotherapy.
  • Beginning in 1998, all patients received highly active antiretroviral therapy before treatment.
  • Seven of 14 anal squamous cell carcinoma patients had their therapy adjusted owing to toxicity.
  • Morbidity included proctocolitis and diarrhea (n = 2) requiring diversion (n = 1), hemorrhagic cystitis (n = 1), neutropenic fever (n = 3), bone marrow suppression (n = 1), and urethral stricture (n = 1).
  • Mean age was 42 years for anal squamous cell carcinoma patients and 36 years for squamous cell carcinoma in situ patients (P = 0.05).
  • Mean CD4 count was 222 cells/ml in patients with infiltrating carcinoma and 200 in the in situ patients (P = NS).
  • One-year and five-year mortality rates, respectively, were 40 percent and 80 percent for infiltrating carcinoma patients and 17 percent and 50 percent for the in situ patients.
  • Both of the in situ patients who died had CD4 counts <20 cells/ml at diagnosis, whereas the rest had CD4 counts >100 cells/ml and are currently without anal disease.
  • Mean CD4 count at diagnosis for all patients who died was 133 cells/ml, whereas for those surviving, it was 261 cells/ml (P = 0.03).
  • Eight (all with infiltrating carcinoma) of the 10 patients who died had persistent anal disease, but none had metastasis.
  • A low CD4 count at diagnosis without highly active antiretroviral therapy predicts a poor prognosis.
  • Because these patients appear to succumb to their HIV status and not the anal disease, anal squamous cell carcinoma should be included with cervical squamous cell carcinoma as an AIDS-defining illness.
  • HIV-positive patients, particularly AIDS patients, with invasive anal cancers and without effective antiretroviral therapy obtain little benefit and significant toxicity from current radiation therapy and chemotherapy.
  • Initiation of highly active antiretroviral therapy in HIV-positive patients before radiation therapy and chemotherapy are begun may decrease toxicity and improve survival.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma in Situ / complications. Carcinoma, Squamous Cell / complications. HIV Infections / complications
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Combined Modality Therapy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome


10. Libby B, Chao D, Schneider BF: Non-surgical treatment of primary female urethral cancer. Rare Tumors; 2010;2(3):e55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-surgical treatment of primary female urethral cancer.
  • Primary carcinomas of the female urethra are extremely rare, with an annual incidence of less than ten in one million.
  • However, there have been several case reports demonstrating the efficacy of chemoradiation in the treatment of female urethral cancer.
  • In this report we present two cases of female primary urethral adenocarcinoma that were treated by concomitant chemotherapy and external beam radiotherapy, followed by interstitial brachytherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139970.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994528
  • [Keywords] NOTNLM ; high-dose rate / low-dose rate. / urethral cancer
  •  go-up   go-down


11. Palou Redorta J, Schatteman P, Huguet Pérez J, Segarra Tomás J, Rosales Bordes A, Algaba F, Villavicencio Mavrich H: Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts. Eur Urol; 2006 May;49(5):834-8; discussion 838
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
  • OBJECTIVES: Bacillus Calmette-Guérin (BCG) has proven its efficacy in the treatment of carcinoma in situ (CIS) of the prostatic urethra.
  • We performed a retrospective study to evaluate the use of intravesical instillations of BCG in patients with carcinoma in situ involving prostatic ducts after complete transurethral resection (TUR).
  • MATERIAL AND METHODS: Eligibility for the study was CIS of the prostatic urethra involving prostatic ducts.
  • TUR loop biopsies of the prostate were performed only when a macroscopic tumor was present.
  • RESULTS: In this retrospective study of 11 patients, 8 (73%) presented with macroscopic tumor in the prostatic urethra.
  • Ten patients (91%) had a simultaneous superficial bladder carcinoma.
  • After a median follow-up of 27 mo (n=10 patients), the response in the prostatic urethra was 82%, and the response in the bladder due to superficial tumor recurrence was 64%.
  • Two patients with residual ductal disease in the prostatic urethra were subsequently treated with cystoprostatectomy and are currently free of disease.
  • Another patient developed distant metastatic disease and died a few months after diagnosis.
  • CONCLUSION: Intravesical BCG is a feasible treatment option for patients with CIS involving prostatic ducts.
  • Obviously, these patients need a careful follow-up with cystoscopy and cytology to detect either recurrence or progression and in those with persistent disease after the initial BCG induction therapy, prompt cystectomy is indicated.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. BCG Vaccine / administration & dosage. Carcinoma in Situ / drug therapy. Prostatic Neoplasms / drug therapy. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Aged, 80 and over. Biopsy. Cystectomy. Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Instillation, Drug. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Transurethral Resection of Prostate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426729.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


12. Parada D, Páez A, Acosta M, Caricote L, Trujillo E, Luigi JC, Farías RM: [Primary urothelial carcinoma of the bulbomembranous urethra. Histologic and immunohistochemical study of a case]. Arch Esp Urol; 2003 Dec;56(10):1144-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary urothelial carcinoma of the bulbomembranous urethra. Histologic and immunohistochemical study of a case].
  • [Transliterated title] Carcinoma urotelial primario de uretra bulbomembranosa. Estudio histológico e inmunohistoquímico de un caso.
  • OBJECTIVE: We report a case of a primary urothelial carcinoma of the bulbomembranous urethra, with special emphasis on histopathological and immunohistochemical findings.
  • METHODS/RESULTS: A 63-year-old man presented urethral obstruction symptoms.
  • A radical phalectomy was performed and a 4.5 x 4 cm bulbomembranous urethral tumor was observed.
  • Histopathological analysis disclosed an urothelial carcinoma, that showed positive immunostaining for cytokeratin AE1/AE3, cytokeratin 7, carcinoembrionic antigen and epithelial membrane antigen.
  • The patient received radiotherapy and adjuvant chemotherapy and is currently free of disease.
  • CONCLUSION: Posterior male urothelial carcinoma of the urethra is a rare neoplasm that usually is mistaken clinically for a benign lesion.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14763421.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


13. Hettiarachchi JA, Johnson GB, Panageas E, Drinis S, Konno S, Das AK: Malignant priapism associated with metastatic urethral carcinoma. Urol Int; 2001;66(2):114-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant priapism associated with metastatic urethral carcinoma.
  • We present a 40-year-old man with malignant priapism secondary to urethral squamous cell carcinoma.
  • Magnetic resonance imaging revealed the tumor originating from the bulbous urethra, extending into the penile urethra and corpora spongiosa and cavernosa.
  • A penile biopsy confirmed poorly differentiated squamous cell carcinoma of the urethra.
  • Despite administration of systemic chemotherapy, the prognosis of the patient has worsened due to the extensive metastatic disease.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / secondary. Priapism / etiology. Urethral Neoplasms / complications. Urethral Neoplasms / secondary

  • Genetic Alliance. consumer health - Priapism.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11223757.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


14. Ouzaid I, Hermieu JF, Dominique S, Fernandez P, Choudat L, Ravery V: Management of adenocarcinoma of the female urethra: case report and brief review. Can J Urol; 2010 Oct;17(5):5404-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adenocarcinoma of the female urethra: case report and brief review.
  • INTRODUCTION: We present a case of a differentiated adenocarcinoma of the female urethra, which caused dysuria and voiding dysfunction.
  • RESULTS: An ultrasound-guided biopsy showed a urethral carcinoma.
  • A magnetic resonance imaging (MRI) scan showed a high-stage tumor.
  • CONCLUSION: Urethral carcinoma is a rare malignancy.
  • A biopsy is necessary to make a diagnosis.
  • MRI is the best imaging for tumor staging.
  • Advanced disease should be treated with a multimodality of options including neoadjuvant radiotherapy given concomitantly with chemotherapy followed by surgery.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Middle Aged. Pelvic Exenteration. Treatment Outcome. Urologic Surgical Procedures / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974039.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  •  go-up   go-down


15. Melonakos EJ, Santucci RA: Treatment of low-grade bulbar transitional cell carcinoma with urethral instillation of mitomycin C. Adv Urol; 2008;:173694
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of low-grade bulbar transitional cell carcinoma with urethral instillation of mitomycin C.
  • A 63-year old man was referred to us after three rapid recurrences of low-grade urethral papillary transitional cell carcinoma of the bulbar urethra, after repeated primary excision.
  • Cystoscopy confirmed 3-4 low-grade urethral transitional cell carcinomas, which were subsequently fulgurated.
  • After urethral healing, a solution of Mitomycin C (40 mg/80 cc) was instilled into the urethra for fifteen minutes and held in place with a penile clamp.
  • Urethral instillations were repeated weekly for six weeks.
  • This case highlights the successful treatment of urethral carcinoma with topical chemotherapy, which is usually reserved for the bladder, using a slight modification of standard technique.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2006 Sep;98(3):526-31 [16925747.001]
  • [Cites] J Urol. 2000 Oct;164(4):1305 [10992392.001]
  • [Cites] J Urol. 2000 Oct;164(4):1306 [10992393.001]
  • [Cites] Urology. 1999 Jun;53(6):1126-32 [10367840.001]
  • (PMID = 18989359.001).
  • [ISSN] 1687-6369
  • [Journal-full-title] Advances in urology
  • [ISO-abbreviation] Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2575232
  •  go-up   go-down


16. Ruoppolo M, Gozo M, Milesi R, Spina R, Fragapane G: [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ]. Urologia; 2010 Oct-Dec;77 Suppl 17:72-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
  • [Transliterated title] Recidiva uretrale di Ca infiltrante dopo trattamento con BCG per Ca in situ vescicale.
  • CIS is a flat, high-grade, non-invasive microscopic urothelial carcinoma.
  • It is considered a precursor of invasive bladder cancer.
  • CIS is classified as primary, secondary or concurrent, when occurred as isolated CIS without cuncurrent papillary tumors, or detected during the follow-up of patients with a previous papillary tumor, or finally in the presence of bladder neoplasm.
  • BCG is widely established as the treatment of choice for CIS with a success rate of approximately 70%.
  • BCG reduces the risk of progression of CIS into invasive carcinoma in 30 to 50% of cases.
  • Direct and prolonged contact between the urothelium and BCG is a prerequisite for successful therapy.
  • Discovery of CIS in the prostatic or membranous urethra represents an ominous sign.
  • CIS may be present only in the epithelial lining of the prostatic urethra or in the ducts, or in the worst case it may be found in the prostatic tissue stroma.
  • Urethral involvement by CIS is at high risk of tumor progression and development of metastases due to reduced thickness of lamina propria and absence of muscolaris mucosa.
  • 83 patients, enrolled from 1/1996 to 12/2005 at our urological department with CIS: primary (focal and multifocal) in 25, secondary in 7 and cuncurrent in 51 (associated with T1bG3 cancer in 37 cases), and urethral CIS in 5 and conservatively treated by TUR and intravescical instillations of BCG, 4 developed afterwords only invasive cancer of the urethra in the absence of bladder involvement.
  • In 2 cases cancer arised from the prostatic fossa after TURP, in 1 from membranous urethra and in the last from prostatic ducts.
  • Among the 4 patients, 3 were treated by cystoprostatourethrectomy and Platinum-based chemotherapy, 1 refused surgical treatment.
  • In the last patient cancer relapsed at 36-month's follow-up.
  • We conclude that prostatic/urethral involvement during follow-up after successful intravesical treatment with BCG in CIS represents a high risk of developing invasive and incontrolled cancer.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / therapy. Carcinoma, Transitional Cell / secondary. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy / methods. Disease Progression. Female. Follow-Up Studies. Humans. Immunotherapy. Male. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Prostatectomy / methods. Prostatic Neoplasms / secondary. Risk. Treatment Outcome. Urethra / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308679.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Organoplatinum Compounds
  •  go-up   go-down


17. Jin B, Pickens A, Shah MB, Turrisi A, Saleh H: Primary large cell neuroendocrine carcinoma of the vagina: cytomorphology of previously unreported case. Diagn Cytopathol; 2010 Dec;38(12):925-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large cell neuroendocrine carcinoma of the vagina: cytomorphology of previously unreported case.
  • Squamous carcinoma is the most common malignancy of the vagina.
  • Other malignancies include adenocarcinoma, melanoma, lymphoma, and very rarely, neuroendocrine carcinoma/small-cell carcinoma.
  • Large cell neuroendocrine carcinoma (LCNEC) has not been reported in this location.
  • Thin prep of vaginal swap was interpreted as atypical glandular cells; however, the biopsies showed a large cell neuroendocrine carcinoma which was confirmed by diffuse strong immunoreactivity to AE1/3, CAM5.2, CK7, and CD56 in the tumor cells.
  • Subsequent clinical workup showed that the patient also had numerous metastatic nodules in the bilateral lungs and a vaginal-urethral fistula caused by the tumor.
  • The patient underwent palliative radiation of pelvis for local pain control and then chemotherapy.
  • Although the vaginal tumor increased in size even after radiation, her symptoms were under control and she was doing well for a short period of time.
  • The patient is still alive but developed brain metastasis a year later after initial diagnosis.
  • Despite its rarity, large cell neuroendocrine cell carcinoma should be included in the differential diagnosis when cytomorphology shows features suggestive of neuroendocrine differentiation.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Antigens, CD56 / metabolism. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20222107.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


18. Hakenberg OW, Franke HJ, Froehner M, Wirth MP: The treatment of primary urethral carcinoma--the dilemmas of a rare condition: experience with partial urethrectomy and adjuvant chemotherapy. Onkologie; 2001 Feb;24(1):48-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of primary urethral carcinoma--the dilemmas of a rare condition: experience with partial urethrectomy and adjuvant chemotherapy.
  • BACKGROUND: Primary urethral carcinoma is a very rare condition, and no large-scale experience with such cases has been published.
  • Treatment will therefore have to follow rules established for the treatment of similar conditions.
  • PATIENTS: Six cases of primary urethral carcinoma (5 male, 1 female) who had been treated at our institution between 1995 and 1999 were retrospectively analyzed.
  • In 3 male cases, a primary urothelial carcinoma of the distal urethra was treated by distal urethrectomy only.
  • In 3 other cases with locally advanced tumors and/or lymph node metastases surgical treatment was followed by adjuvant cisplatinum-containing chemotherapy.
  • RESULTS: In the 3 cases with distal urethral carcinoma, partial urethrectomy with preservation of the penis resulted in cure, with a follow-up of 12-71 months.
  • In the cases with advanced disease, adjuvant chemotherapy after surgery has resulted in complete remissions in all 3 cases, with a follow-up of 4-47 months at present.
  • CONCLUSIONS: In localized, noninvasive carcinoma of the distal male urethra, partial urethrectomy seems adequate and the avoidance of penile amputation justified.
  • In advanced cases, after local excision and lymphadenectomy adjuvant chemotherapy which by necessity must follow the guidelines established for the treatment of other urothelial or squamous cell malignancies seems to be beneficial.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Urethra / pathology. Urethra / surgery

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441281.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Tefilli MV, Stefani SD, Mariano MB: Urethral metastasis of lung carcinoma with germinative cell features. Int Braz J Urol; 2003 Sep-Oct;29(5):431-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral metastasis of lung carcinoma with germinative cell features.
  • INTRODUCTION: We present the case of a patient with urethral metastasis of a lung carcinoma with germinative cell features.
  • Patient was being treated with chemotherapy and radiotherapy during the past 3 months due to primary carcinoma of the lung with brain metastasis.
  • Urethrocistoscopy and nuclear magnetic resonance imaging revealed a stenosing mass invading the bulbomembranous urethra.
  • No other tumor was found.
  • Biopsy specimens, obtained from the lung, brain and urethra tumors, revealed the same neoplasia, with definitive diagnosis being undifferentiated giant cell carcinoma of the lung with germinative features.
  • Considering his clinical condition and poor prognosis, a decision was made to treat the patient only clinically.
  • COMMENTS: As far as we were able to access, urethral metastasis from lung carcinoma had never been described in the indexed literature.
  • Due to the extremely limited experience with these tumors, there is not a defined treatment and the prognosis remains quite poor.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15745589.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


20. Koizumi T, Bando S, Kanda K, Inai T: [Two cases of primary female urethral cancer]. Nihon Hinyokika Gakkai Zasshi; 2007 Sep;98(6):790-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of primary female urethral cancer].
  • Herein, we report two cases of female urethral cancer.
  • Magnetic resonance imaging (MRI) revealed a urethral tumor in both cases.
  • Histopathological examination of transperineal biopsy specimens from both patients suggested clear cell adenocarcinoma in case 1 and squamous cell carcinoma in case 2.
  • With reference to case 1, obturator lymph node metastases were observed during surgery, and treatment comprised combined radiotherapy to 60 Gy and chemotherapy with 5-fluorouracil and cisplatin following surgery.
  • However, metastases appeared in the lung 6 months after initial treatment and she died 20 months after surgery.
  • For case 2, tumor marker failure was observed 5 months after surgery.
  • The same combined treatment was performed and a complete response was obtained.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Urethral cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929463.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


21. Cheng L, Foster SR, MacLennan GT, Lopez-Beltran A, Zhang S, Montironi R: Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum? J Urol; 2008 Oct;180(4):1235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Inflammatory myofibroblastic tumor of the genitourinary tract is a spindled soft tissue lesion that is often mistaken for sarcoma.
  • The relationship between inflammatory myofibroblastic tumor and other morphologically similar entities has been a long-standing source of controversy.
  • We investigated whether inflammatory myofibroblastic tumors in adults and children are the same entity, and whether inflammatory myofibroblastic tumor is part of a biological spectrum that includes benign and malignant entities at opposite ends.
  • CONCLUSIONS: Inflammatory myofibroblastic tumor of the genitourinary tract should be considered a neoplasm of uncertain malignant potential, and routine surveillance and close clinical followup are recommended.
  • Aggressive therapy (radical cystectomy, radiation or chemotherapy) is unwarranted given the indolent and often benign clinical course for the majority of cases.
  • To understand the diagnostic and prognostic implications future emphasis should be placed on the link between genetic abnormalities, and clinical course, therapeutic response and ultimate outcome.
  • [MeSH-major] Carcinoma / pathology. Granuloma, Plasma Cell / pathology. Sarcoma / pathology. Urogenital Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Incidence. Neoplasm Staging. Prognosis. Risk Assessment. Ureteral Neoplasms / diagnosis. Ureteral Neoplasms / pathology. Urethral Neoplasms / diagnosis. Urethral Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707729.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


22. Xiao MZ, Gou X, He ZM: [Diagnosis and treatment of urethral condyloma acuminatum in male patients]. Zhonghua Nan Ke Xue; 2002;8(2):112-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of urethral condyloma acuminatum in male patients].
  • OBJECTIVES: To present experience on the diagnosis and treatment of urethral condyloma acuminatum (CA) in male patients.
  • METHODS: Twenty-one cases of urethral CA were studied.
  • The lesion of urethral meatus and intraurethal were resected by electrofulguration or operation and Urethroscopy, respectively.
  • All patients were received intraurethral instillation and local therapy of 5% 5-fluorouracil solution.
  • CONCLUSIONS: Transurethral endoscopy is a reliable diagnosis and treatment method.
  • Intraurethral instillation and local therapy of 5% 5-fluorouracil solution may prevent the recurrence of CA.
  • [MeSH-major] Condylomata Acuminata / diagnosis. Fluorouracil / therapeutic use. Urethral Diseases / diagnosis
  • [MeSH-minor] Follow-Up Studies. Humans. Instillation, Drug. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Urethral Disorders.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479023.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Karnes RJ, Breau RH, Lightner DJ: Surgery for urethral cancer. Urol Clin North Am; 2010 Aug;37(3):445-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for urethral cancer.
  • Primary urethral cancers represent less than 1% of genitourinary malignancy.
  • Given this is an uncommon disease, there are limited data to guide diagnostic and treatment strategies.
  • Surgical extirpation remains the standard for most patients, with the addition of chemotherapy and radiation therapy in select patients.
  • The surgical approach to urethral cancer depends largely on the location and extent of the tumor.
  • [MeSH-major] Urethral Neoplasms / surgery

  • Genetic Alliance. consumer health - Urethral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674699.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Hamasaki T, Kondo Y, Ogata Y, Yoshida K, Kimura G, Shimizu H, Nishimura T: Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder. Int J Clin Oncol; 2010 Feb;15(1):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.
  • Pathological examination diagnosed poorly differentiated urothelial carcinoma of the urethra with broad prostatic permeation.
  • Random bladder biopsies showed no malignancy, but a second TUR-P revealed urothelial carcinoma in the prostate and bladder neck.
  • Computed tomography (CT) showed lymph node metastases from para-aortic to right/left external iliac and left obturator nodes, so clinical stage T3N2M0 carcinoma of the prostatic urethra was diagnosed.
  • Given the presence of lymph node metastases, neoadjuvant chemotherapy using cisplatin 70 mg/m(2), ifosfamide 1.2 g/m(2) and docetaxel 70 mg/m(2) (PIT) was considered.
  • After chemotherapy, CT showed complete response (CR) of all lymph nodes.
  • Pathological findings of surgical specimens showed no residual carcinoma in the prostatic urethra or lymph nodes, although prostatic adenocarcinoma was recognized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Prostatic Neoplasms / secondary. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Aged. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Prostatectomy. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1996 Nov;48(5):703-10 [8911513.001]
  • [Cites] Am J Clin Pathol. 1963 Aug;40:183-9 [14060023.001]
  • [Cites] J Urol. 1973 Mar;109(3):457-60 [4348139.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Hinyokika Kiyo. 2000 Jul;46(7):495-8 [10965459.001]
  • [Cites] Urology. 1984 Dec;24(6):544-9 [6506393.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Br J Urol. 1979 Dec;51(6):575-8 [534844.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1671-8 [10738226.001]
  • [Cites] Urology. 2007 Jan;69(1 Suppl):50-61 [17280908.001]
  • [Cites] Hinyokika Kiyo. 1970 Apr;16(4):157-61 [5463380.001]
  • (PMID = 20087614.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Murphy DR, Morris NJ: Transitional cell carcinoma of the urethra [correction of ureter] in a patient with buttock pain: a case report. Arch Phys Med Rehabil; 2008 Jan;89(1):150-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the urethra [correction of ureter] in a patient with buttock pain: a case report.
  • This case reports on a patient with an unusual presentation of a rare tumor: urethral transitional cell carcinoma (TCC).
  • Urethral TCC occurs in approximately 0.7% to 4.0% of patients who have had primary bladder cancer.
  • The patient was initially suspected to have piriformis syndrome, but when he did not respond as expected to treatment, and because of his history of primary bladder cancer, further evaluation was undertaken and the diagnosis was made.
  • The patient responded well to radiation and chemotherapy.
  • Musculoskeletal physicians should be particularly suspicious of the presence of urethral TCC in a patient with a history of primary bladder cancer who reports low back or buttock pain, particularly if the patient does not respond quickly to treatment.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Low Back Pain / etiology. Urethral Neoplasms / complications
  • [MeSH-minor] Aged. Buttocks. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Neoplasms, Multiple Primary. Prostatic Neoplasms. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164345.001).
  • [ISSN] 1532-821X
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Sopena JM, González JA, Queralt MP, Sariol JC, Redorta JP, Mavrich HV: [Metastasic urethral squamous-cell a cancer]. Actas Urol Esp; 2009 Jun;33(6):712-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasic urethral squamous-cell a cancer].
  • [Transliterated title] Carcinoma escamoso de uretra metastático.
  • Urethral cancer is an infrequent pathology, less than 1% of the genitourinary tumors.
  • The most frequent histology being squamous cell carcinoma.
  • The interval between the onset of symptoms and diagnosis may be as long as three years.
  • Therefore most of these tumors are locally advanced at the time of diagnosis with generally poor prognosis despite aggressive treatment.
  • Therapeutic management varies with the stage and location of the lesion.
  • Because of the rarity of this pathology, no consensus has been reached on treatment modalities, but seems to be that must be a multimodal one, including surgery, radiotherapy and chemotherapy.
  • We present the case of an 80 year-old male, with a diagnosis of urethral squamous-cell cancer, locally advanced at the time of diagnosis.
  • The patient underwent chemotherapy and radiotherapy with evidence of quick progression thereafter.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Urethral Neoplasms / secondary

  • Genetic Alliance. consumer health - Urethral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711759.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


27. Buechner SA: Common skin disorders of the penis. BJU Int; 2002 Sep;90(5):498-506
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review highlights the clinical features, diagnosis and treatment of the most common dermatoses of the male genitalia.
  • The most common causal agents for condyloma acuminatum are low-risk HPV 6 and 11; high-risk HPV types 16 and 18 are associated with premalignant and malignant lesions.
  • Treatment for genital warts remains unsatisfactory; recurrences are common.
  • Imiquimod, a new topical immunotherapeutic agent, which induces interferon and other cytokines, has the potential to be a first-line therapy for genital warts.
  • Oral ivermectin, a highly active antiparasitic drug, is likely to be the treatment of choice, but until approval is granted it should be reserved for special forms of scabies.
  • The penile form is a common cause of phimosis in uncircumcised men; involvement of the urethral meatus may lead to progressive meatal stenosis.
  • Squamous cell carcinoma (SCC) in situ, e.g. erythroplasia of Queyrat and Bowen's disease, cannot be excluded clinically; their apparent clinical benignity may lead to lengthy periods of misdiagnosis and biopsy is required to confirm the diagnosis.
  • SCC is the most common malignancy of the penis and the role of oncogenic HPV-types has been also established in SCC of the penis.
  • Prevention of SCC of the penis presupposes an identification of risk factors, early detection of all pre-cancerous lesions and treatment of phimosis.
  • [MeSH-minor] Balanitis / diagnosis. Balanitis / therapy. Humans. Male. Mite Infestations / diagnosis. Mite Infestations / therapy. Penile Neoplasms / diagnosis. Penile Neoplasms / therapy. Skin Diseases, Parasitic / diagnosis. Skin Diseases, Parasitic / therapy. Skin Diseases, Viral / diagnosis. Skin Diseases, Viral / therapy


28. Das S, Tunuguntla HS: Balanitis xerotica obliterans--a review. World J Urol; 2000 Dec;18(6):382-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many cases of BXO occurring after circumcision may be cases of secondary phimosis due to BXO not being recognized at the time of surgery.
  • Biopsy of the lesions is not essential in all cases and is indicated to differentiate from penile cancer and in atypical cases.
  • Early diagnosis and treatment of BXO are very important in preventing the urological complications of the diseases such as urethral stricture.
  • Treatment of BXO depends on the anatomic location of the lesions and their extent and severity, together with the rapidity of progression of the disease process.
  • The treatment may vary from topical corticosteroids, laser vaporization in early cases to meatoplasty and urethroplasty in extensive cases.
  • Topical pharmacotherapy is useful in the early stages to reduce the initial symptoms and slow down the progression, but is not effective in all cases and is not the curative treatment of disease.
  • Meatal stenosis, phimosis, scar adhesions, fissures, erosions of glans and prepuce and involvement of the urethra are indications for surgical treatment.
  • Surgery seems to be the only treatment that can relieve the symptoms of advanced disease.
  • BXO involving anterior urethra can be treated by 2-stage urethroplasty or substitution urethroplasty.
  • The complete excision of the stricture and flap urethroplasty seems to be better than a 2-stage procedure.
  • However, at the present time, it is not possible to say that surgery can completely resolve this chronic and progressive disease.
  • Despite many reports in the literature of cases of BXO associated with squamous cell carcinoma, the etiologic relationship between the two conditions is uncertain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11204255.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 27
  •  go-up   go-down


29. Morikawa H, Cho M, Takada S, Fujimoto K, Uemura H, Ozono S, Hirao Y, Natsume O: [A case of primary transitional cell carcinoma of the prostate]. Hinyokika Kiyo; 2003 Jun;49(6):357-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary transitional cell carcinoma of the prostate].
  • He had had a hemi-thyroidectomy for thyroid cancer and right cervical lymphadenectomy three years and one year, respectively, before this visit.
  • Prostate cancer was strongly suspected by transrectal examination with prostate specific antigen (PSA) elevated to 77.8 ng/ml.
  • Pathological diagnosis of prostate biopsy specimen was transitional cell carcinoma with grade 3 malignancy and negative staining for PSA.
  • Endoscopic examination showed a normal appearance of bladder and prostatic urethral epithelium.
  • Endocrine therapy (goserelin acetate depot, bicalutamide) and systemic chemotherapy (methotrexate, epirubicin, cisplatin) were performed combined with irradiation to right ischium metastasis.
  • Two months later, he showed a complete response in PSA and partial response in lymph node metastases, but died of cancer 13 months later.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Combined Modality Therapy. Fatal Outcome. Humans. Male. Prostate-Specific Antigen / blood. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894737.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 11
  •  go-up   go-down


30. Segura Huerta A, Molina Saera J, Palomar Abad L, Pellín Ariño L, Guerrero Zotano A, Calderero Aragón V: [Advanced urethral carcinoma. Which is the best management of a infrequent disease?]. Actas Urol Esp; 2004 Jan;28(1):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced urethral carcinoma. Which is the best management of a infrequent disease?].
  • [Transliterated title] Carcinoma uretral con extensión locorregional importante. Cómo manejamos una patología infrecuente?
  • Urethral cancer is an uncommon tumor (<0.1% of all genitourinary neoplasms).
  • Most of them are squamous carcinoma, adenocarcinomas are about 5% of all urethral cancer.
  • Surgery is the only curative treatment.
  • Chemotherapy (CT) and radiotherapy (RT) must be used in patients in which surgery is not possible.
  • Due to the low incidence of this neoplasm is not well established the best therapeutic approach.
  • We present the case of a female (35 years old) with a diagnosis of urethral adenocarcinoma.
  • Surgery was impossible and the patient received chemotherapy and radiotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Urethral Neoplasms / therapy

  • Genetic Alliance. consumer health - Best Vitelliform Macular Dystrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15046483.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. VanderMolen LA, Sheehy PF, Dillman RO: Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest; 2002;20(2):206-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of transitional cell carcinoma of the urethra with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urethral Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11901541.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


32. Parisi S, Troiano M, Corsa P, Raguso A, Cossa S, Piazzolla EE, Munafò T, Sanpaolo G, Natuno A, Maiello E: Role of external radiation therapy in urinary cancers. Ann Oncol; 2007 Jun;18 Suppl 6:vi157-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of external radiation therapy in urinary cancers.
  • Invasive urinary tumors are relatively rare and their treatment may cause important changes in urinary, sexual, and social functions.
  • A systematic review of external radiation therapy studies in urinary cancers has been carried out.
  • There are few controlled clinical trials using adjuvant or radical radiotherapy +/- chemotherapy in kidney, ureter, and urethra cancers; there are several reports of muscle-invasive bladder cancer using multimodality treatment: intravesical surgery and neo-adjuvant chemotherapy to radiotherapy or concomitant radiochemotherapy with organ preservation.
  • The conclusions reached for renal cancer are controversial; urethra and ureter cancers data are few and inconclusive; sufficient data now exist in literature to demonstrate that conservative management with organ preservation, for muscle-invasive bladder cancer, is a valid alternative to radical cystectomy, viewed as the gold standard.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591812.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 34
  •  go-up   go-down


33. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE: Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol; 2010 Oct;58(4):486-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The need for and intensity of follow-up to detect disease recurrence after radical cystectomy (RC) for transitional cell carcinoma (TCC) remains a matter for debate.
  • OBJECTIVE: To determine whether diagnosis of asymptomatic recurrence after RC by routine follow-up investigations confers a survival benefit versus symptomatic recurrence.
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre.
  • MEASUREMENTS: Cancer-specific survival (CSS) and overall survival (OS) probability for asymptomatic and symptomatic recurrent patients were estimated using the Kaplan-Meier method.
  • The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models.
  • Routine follow-up mostly detected lung metastases and urethral recurrences, while symptoms were predominantly the result of bone metastases and concomitant pelvic/distant recurrences.
  • Of 24 patients with urethral recurrences, 13 had carcinoma in situ (CIS).
  • Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease.
  • In multivariable analysis, mode of recurrence diagnosis and site of initial recurrence were the only independent predictors of CSS and OS.
  • Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Ileum / transplantation. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors


34. Karmouni T, Rioux-Leclercq N, Bensalah K, Alva A, Patard JJ, Guillé F, Lobel B: [Primary neuroendocrine carcinoma of the bladder: diagnosis and treatment]. Prog Urol; 2000 Sep;10(4):590-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary neuroendocrine carcinoma of the bladder: diagnosis and treatment].
  • [Transliterated title] Carcinomes neuroendocrines primitifs de vessie: diagnostic et traitement.
  • This study analyzed the diagnostic criteria and therapeutic results obtained in 5 consecutive patients over a 3-year period.
  • MATERIALS AND METHODS: 5 patients (3 men and 2 women) suffering from primary small cell carcinoma of the bladder were evaluated.
  • Histological diagnosis, treatment modalities and outcome were reviewed.
  • All tumours were invasive at the time of diagnosis.
  • 4 patients were treated by trans urethral resection alone, 2 of whom also received adjuvant radio-chemotherapy.
  • The 4 patients treated by conservative treatment modality had progression and a shorter survival, in contrast with patient treated by radical cystectomy.
  • Treatment must consist of a combination of neoadjuvant or adjuvant chemotherapy and surgery to achieve the best results.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064903.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


35. Dimarco DS, Dimarco CS, Zincke H, Webb MJ, Bass SE, Slezak JM, Lightner DJ: Surgical treatment for local control of female urethral carcinoma. Urol Oncol; 2004 Sep-Oct;22(5):404-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for local control of female urethral carcinoma.
  • We reviewed 53 patients (mean age 63 years) who underwent partial urethrectomy (n = 26) or radical extirpation (n = 27) for primary female urethral cancer from 1948 through 1999.
  • Clinical stage, histology, high pathologic stage (3 or 4) and grade, tumor location, nodal status, surgery type, adjuvant therapy, and treatment decade were candidate outcome predictors.
  • For adjuvant therapy, 20 patients had radiation (8 preoperatively), 2 had radiation + chemotherapy, and 1 had chemotherapy alone.
  • Of patients undergoing partial urethrectomy for pT1-3 tumors, 6/27 (22%) had urethral recurrence.
  • Recurrence-free survival +/- standard error (SE) at 10 years was 45 + 8%.
  • Those who recurred had a cancer mortality rate of 71% at 5 years postrecurrence.
  • The estimated 10-year cancer-specific survival (CSS) and crude survival (CS) rates were 60 +/- 8% and 42 +/- 7%, respectively.
  • Upon review, partial urethrectomy resulted in a high urethral recurrence rate (22%) with no bladder recurrences.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464921.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Tanaka H, Masuda H, Komai Y, Yokoyama M, Iwai A, Numao N, Sakai Y, Saito K, Fujii Y, Kobayashi T, Kawakami S, Kihara K: [Primary adenocarcinoma of the female urethra treated by multimodal therapy]. Hinyokika Kiyo; 2009 Jan;55(1):43-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the female urethra treated by multimodal therapy].
  • Magnetic resonance imaging showed a tumor surrounding the urethra, which invaded to the vesical triangle and the anterior vaginal wall.
  • Serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9 were elevated, but squamous cell carcinoma antigen and prostate specific antigen were within normal limits.
  • First, the patient received local chemoradiotherapy and systemic chemotherapy using a fluoropyrimidine drug TS-1 and cisplatin.
  • The tumor markers declined to within normal limits after this preoperative therapy.
  • The final diagnosis was urethral adenocarcinoma, pT4N0, Stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227213.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Bakkali H, Benjaafar N, Mansouri A, Errihani H, Kettani F, Benchekroun A, El Gueddari Bel K: [Primary adenocarcinoma of the male urethra. A case report]. Cancer Radiother; 2002 Dec;6(6):358-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the male urethra. A case report].
  • [Transliterated title] L'adénocarcinome primitif de l'urètre masculin. A propos d'un cas.
  • Primary adenocarcinoma of the male urethra is very uncommon, accounts for 5% of primary urethral cancers.
  • All types of urethral carcinomas account for less than 1% of urinary malignancies in man.
  • The prognosis remains poor despite the wide surgical treatment.
  • The place of chemotherapy combined with radiotherapy must be defined by other studies.
  • We report a case of primary locally advanced adenocarcinoma arising in the bulbo-membranous urethra.
  • He was treated by combined external beam radiotherapy (total dose 67Gy) and chemotherapy (Cisplatinum).
  • A marked reduction of tumor volume has been noted but the patient died because of the appearance of bone metastasis which failed to the systemic therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Neoplasm Metastasis. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504773.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Bryant CS, Shah JP, Triest JA, Schimp VL, Morris RT: Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus. Gynecol Oncol; 2008 Dec;111(3):552-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus.
  • BACKGROUND: Chemotherapy remains an essential part of the treatment of advanced ovarian cancer.
  • Intraperitoneal (IP) administration has been demonstrated to provide a survival advantage over intravenous chemotherapy in three phase 3 studies.
  • However, IP catheter complications have been a significant factor in aborting IP therapy.
  • CASE: A 42-year-old woman receiving IP chemotherapy for carcinoma of the ovary presented with complaints of incontinence.
  • Examination revealed the catheter protruding through the external urethral meatus.
  • IP chemotherapy was resumed 16 days postoperatively without incident.
  • Increased usage of IP chemotherapy may offer new challenges in the diagnosis and management of catheter-related complications.
  • [MeSH-minor] Adult. Female. Humans. Infusions, Parenteral. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289650.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Koontz BF, Lee WR: Carcinoma of the urethra: radiation oncology. Urol Clin North Am; 2010 Aug;37(3):459-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the urethra: radiation oncology.
  • Urethral cancer is a rare but aggressive neoplasm.
  • Early-stage distal lesions can be successfully treated with a single modality.
  • Results for definitive radiotherapy using either or both external beam radiation therapy and brachytherapy have shown excellent cure rates in men and women.
  • Advanced tumors, however, have poor outcomes with single modality treatment.
  • Results have been improved using a combination of radiotherapy and chemotherapy, chiefly 5-fluorouracil and mitomycin C.
  • [MeSH-major] Carcinoma / radiotherapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674700.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Gómez Díaz ME, Castaño González-Coto D, Cuervo Calvo J, Muruamendiaraz Fernández V: [Cancer of the female urethra. Report of a new case a review of the literature]. Arch Esp Urol; 2002 Jun;55(5):568-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the female urethra. Report of a new case a review of the literature].
  • [Transliterated title] Cáncer de uretra femenino. Aportación de un nuevo caso y revisión de la literatura.
  • OBJECTIVE: To review the main features of female urethral cancer, the only genitourinary neoplasm with a predilection for women, the ratio being 4:1.
  • Female urethral cancer is an uncommon neoplasm that accounts for only 0.02% of all cancers found in women.
  • METHODS: A case of female urethral cancer in a 52-year-old woman is presented.
  • RESULTS/CONCLUSIONS: Female urethral cancer is an uncommon neoplasm.
  • For patients with Ta-2N0M0 tumors, multimodality therapy may not be required.
  • For patients with T3-4N0M0 tumors, the best results are obtained with multimodal radiation and chemotherapy with surgical resection.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174428.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 9
  •  go-up   go-down


41. Palou J, Baniel J, Klotz L, Wood D, Cookson M, Lerner S, Horie S, Schoenberg M, Angulo J, Bassi P: Urothelial carcinoma of the prostate. Urology; 2007 Jan;69(1 Suppl):50-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma of the prostate.
  • This study was conducted to explore the diagnosis and management of urothelial carcinoma of the prostate in superficial disease and carcinoma in situ, stromal invasion, primary urothelial carcinoma, and urethral recurrence after radical surgery.
  • A consensus conference convened by the World Health Organization (WHO) and the Société Internationale d'Urologie (SIU) reviewed the diagnosis and management of urothelial carcinoma of the bladder.
  • English-language literature about urothelial carcinoma of the prostate was identified and reviewed.
  • Evidence-based recommendations for the diagnosis and management of urothelial carcinoma were made.
  • Many recommendations were level 3 or 4 citations involving the diagnosis and management of superficial urothelial carcinoma; a few were level 2 citations.
  • Level 1 citations related only to chemotherapy and radiotherapy in patients with stromal invasion, although these were not related specifically to invasive prostatic involvement.
  • Published reports on the diagnosis and treatment of superficial urothelial disease of the prostate primarily consist of short case series from individual centers.
  • In invasive disease of the prostate, the only large series were designed to investigate invasive bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell. Prostatic Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Global Health. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280908.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


42. Iborra F, Rigaud J, Bastide C, Mottet N, les membres du sous-comité organes génitaux externes du comité de cancérologie de l'AFU: [Treatment of primary urethral carcinoma. Guidelines from the French Urological Association. Cancer committee]. Prog Urol; 2009 Mar;19(3):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of primary urethral carcinoma. Guidelines from the French Urological Association. Cancer committee].
  • [Transliterated title] Prise en charge thérapeutique des tumeurs de l'urètre. Recommandations du comité de cancérologie de l'Association française d'urologie.
  • The litterature dealing with the treatment of primary uretral carcinoma is very limited.
  • The treatment modality is mainly based on the lesion topography and not on the histology.
  • For more advanced lesions, the combination of radiotherapy and chemotherapy is the standard of care.
  • [MeSH-major] Carcinoma / therapy. Urethral Neoplasms / therapy
  • [MeSH-minor] BCG Vaccine / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. France. Humans. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Urethral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19268254.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Practice Guideline; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / BCG Vaccine
  • [Number-of-references] 28
  •  go-up   go-down


43. Trabulsi EJ, Hoffman-Censits J: Chemotherapy for penile and urethral carcinoma. Urol Clin North Am; 2010 Aug;37(3):467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for penile and urethral carcinoma.
  • Although surgery is the mainstay of curative treatment of carcinomas of the penis and urethra, there is a role for systemic cytotoxic chemotherapy for locally advanced, unresectable, or metastatic tumors.
  • Although this field is limited by a paucity of clinical trials or prospective data, the available single institutional retrospective reviews indicate that multi-agent cisplatin-based combination chemotherapy regimens have significant activity and may allow curative surgery for patients with otherwise unresectable tumors.
  • This article reviews the available literature on chemotherapy for carcinoma of the penis and urethra in the neoadjuvant, adjuvant, and metastatic setting.
  • [MeSH-major] Penile Neoplasms / drug therapy. Urethral Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Chemotherapy, Adjuvant. Humans. Male. Neoadjuvant Therapy. Taxoids / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674701.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids
  • [Number-of-references] 34
  •  go-up   go-down


44. Fekak H, Rabu R, Joual A, Bennani S, Moufid K, Sarf S, Debragh A, el Mimu M, Benjelloun S: [Intradiverticular bladder tumors. Three case reports]. Ann Urol (Paris); 2002 Jan;36(1):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs de vessie intradiverticulaires. A propos de trois cas.
  • We reported three cases of bladder tumours in vesical diverticula, with delay of diagnosis two, eight and twelve months respectively.
  • The radiology exploration suspected the diagnosis and the histology biopsy confirmed a diagnosis of primary transitional cell carcinoma in two cases: PTa GI and T2 GII, and in an other case it was a invasive epidermoid carcinoma.
  • The first patient was dead by urethral resection of the bladder tumour.
  • The treatment consisted of radiotherapy and chemotherapy.
  • We insisted of the particularity diagnosis, histology and therapeutic for bladder tumour in vesical diverticula and the early diagnosis in order to have a good prognosis.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Diverticulum / pathology. Neoplasm Invasiveness. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11859579.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement